Silence (SLN) Q2 Revenue Drops 71%
Silence Therapeutics Plc (NASDAQ:SLN), a biotechnology company focused on developing RNA interference (RNAi) therapeutics, released its second quarter results on August 7, 2025. The company reported GAAP revenue of $224 thousand, far below analyst estimates, while net loss widened year over year to $27.4 million from $19.8 million. GAAP revenue was $0.22 million, missing the $7.03 million estimate by 96.8%. The quarter showed continued investment in research and development along with some operational efficiencies in general and administrative expenses. Progress continued for the lead clinical programs, but commercial revenues remain limited.
Source: Analyst estimates for the quarter provided by FactSet.
Silence Therapeutics Plc develops RNA interference therapies using its proprietary mRNAi GOLD platform. This technology aims to silence disease-related genes, mainly targeting the liver through a special delivery mechanism called GalNAc conjugation. Its approach enables precise and durable suppression of targeted genes, potentially unlocking new treatments for cardiovascular, hematology, and rare genetic diseases.
Source Fool.com
